

<b>Reference:</b>	FOI.20422.26
<b>Subject:</b>	Dermatology and Rheumatology
<b>Date of Request:</b>	13 May 2026

**Request and response:**

1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients for some of the medications due to the low numbers (less than 5) and have therefore, replaced the figures in the tables with an asterisk (\*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act (FOIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

The UHB provides within the table below as requested, the number of Dermatology patients and the number of new Psoriasis patients, treated with the listed medications, during the period 1 January to 31 March 2026.

	<b>Total Dermatology department</b>	<b>Psoriasis</b>
Adalimumab [Humira]	0	0
Adalimumab [All Biosimilars]	10	*
Apremilast [Otezla]	0	0
Apremilast [Generic]	0	0
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	0	0
Infliximab [Remicade]	0	0
Infliximab [All Biosimilars]	0	0
Ustekinumab [Stelara]	0	0
Ustekinumab [All Biosimilars]	*	*
Bimekizumab [Bimzelx]	0	0
Brodalumab [Kyntheum]	0	0

Certolizumab [Cimzia]	0	0
Deucravacitinib [Sotyktu]	0	0
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	0	0
Ixekizumab [Taltz]	0	0
Risankizumab [Skyrizi]	*	*
Secukinumab [Cosentyx]	*	0
Spesolimab [Spevigo]	0	0
Tildrakizumab [Illumetri]	0	0

2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

The UHB provides within the table overleaf as requested, the number of new Rheumatology patients, treated for the named conditions with the named medications, during the period 1 January to 31 March 2026.

	<b>Total Rheumatology department</b>	<b>Axial Spondyloarthritis (axSpA)</b>	<b>Rheumatoid Arthritis (RA)</b>	<b>Psoriatic Arthritis (PsA)</b>
Abatacept [Orencia]	*		*	0
Adalimumab [Humira]	0	0	0	0
Adalimumab [All Biosimilars]	57	29	15	*
Apremilast [Otezla]	0			0
Apremilast [Generic]	0			0
Baricitinib [Olumiant]	0		0	
Bimekizumab [Bimzelx]	0	0		0
Certolizumab [Cimzia]	*	0	0	0
Etanercept [Enbrel]	0	0	0	0

Etanercept [All Biosimilars]	5	*	*	0
Filgotinib [Jyseleca]	*		0	
Golimumab [Simponi]	*	*	0	0
Golimumab [All Biosimilars]	0	0	0	0
Guselkumab [Tremfya]	0		0	0
Infliximab [Remicade]	0	0	0	0
Infliximab [All Biosimilars]	5	*	0	0
Ixekizumab [Taltz]	0	0		0
Risankizumab [Skyrizi]	*			0
Rituximab [MabThera]	0		0	
Rituximab [Biosimilars]	8		0	
Sarilumab [Kevzara]	0		0	
Secukinumab [Cosentyx]	*	0	*	0
Tocilizumab [RoActemra]	0	0	0	0
Tocilizumab [Biosimilars]	57	29	15	*
Tofacitinib [Xeljanz]	0	0	0	0
Upadacitinib [Rinvoq]	0	0	0	0
Ustekinumab [Stelara]	0		0	0
Ustekinumab Biosimilar	0	0		0